Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
J Psychiatr Res ; 44(14): 944-55, 2010 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-20378129

RESUMO

Cannabis is the most common secondary illicit substance in methamphetamine (METH) users, yet the outcomes of the concurrent consumption of both substances remain elusive. Capitalizing on recent findings on the implication of CB1 cannabinoid receptors in the behavioral effects of METH, we hypothesized that METH-induced neurotoxicity may alter the brain expression of CB1, thereby affecting its role in behavioral functions. To test this possibility, we subjected rats to a well-characterized model of METH neurotoxicity (4 mg/kg, subcutaneous × 4 injections, 2 h apart), and analyzed their CB1 receptor brain expression three weeks later. METH exposure resulted in significant enhancements of CB1 receptor expression across several brain regions, including prefrontal cortex, caudate-putamen, basolateral amygdala, CA1 hippocampal region and perirhinal cortex. In parallel, a different group of METH-exposed rats was used to explore the responsiveness to the potent cannabinoid agonist WIN 55,212-2 (WIN) (0.5-1 mg/kg, intraperitoneal), within several paradigms for the assessment of emotional and cognitive functions, such as open field, object exploration and recognition, and startle reflex. WIN induced anxiolytic-like effects in METH-exposed rats and anxiogenic-like effects in saline-treated controls. Furthermore, METH-exposed animals exhibited a significantly lower impact of WIN on the attenuation of exploratory behaviors and short-term (90 min) recognition memory. Conversely, METH neurotoxicity did not significantly affect WIN-induced reductions in locomotor activity, exploration time and acoustic startle. These results suggest that METH neurotoxicity may alter the vulnerability to select behavioral effects of cannabis, by inducing distinct regional variations in the expression of CB1 receptors.


Assuntos
Comportamento Animal/efeitos dos fármacos , Encéfalo/metabolismo , Síndromes Neurotóxicas/metabolismo , Síndromes Neurotóxicas/psicologia , Receptor CB1 de Canabinoide/metabolismo , Estimulação Acústica/métodos , Tonsila do Cerebelo/metabolismo , Animais , Benzoxazinas/administração & dosagem , Benzoxazinas/farmacologia , Encéfalo/efeitos dos fármacos , Região CA1 Hipocampal/metabolismo , Agonistas de Receptores de Canabinoides , Núcleo Caudado/metabolismo , Estimulantes do Sistema Nervoso Central/administração & dosagem , Estimulantes do Sistema Nervoso Central/toxicidade , Modelos Animais de Doenças , Comportamento Exploratório/efeitos dos fármacos , Masculino , Memória/efeitos dos fármacos , Metanfetamina , Morfolinas/administração & dosagem , Morfolinas/farmacologia , Atividade Motora/efeitos dos fármacos , Naftalenos/administração & dosagem , Naftalenos/farmacologia , Córtex Pré-Frontal/metabolismo , Putamen/metabolismo , Ratos , Ratos Sprague-Dawley , Reflexo de Sobressalto/efeitos dos fármacos , Regulação para Cima/efeitos dos fármacos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...